Private investment giant Apollo Global Management has said before that a major limitation on reaching its goal of $1.5 trillion in assets might not be raising enough money, but finding enough ...

A Bass Strait shipping company director says delays in approving the use of Apollo Bay port for livestock transport from King Island are "no longer politically and publicly tenable." ...

Apollo Green Energy has been actively bidding in tenders issued by Central and state governments and public sector companies to meet its ₹10,000-crore order book target. The company prioritises ...

The group of defendants in the long-running YSL trial is quickly dwindling. After Young Thug’s bombshell guilty plea on October 31, leading to his release from prison, just two defendants remain ...

Nike is launching its Book 1 “Court Purple” sunset sneakers to celebrate the beautiful colors of the sky during sunset in Phoenix, Arizona. The shoes are designed with inputs from NBA star Devin ...

A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.

In this image from video, former police officer Adam Coy, left, sits in court in Columbus, Ohio, on Monday, Nov. 4, 2024, before the verdict is read in his trial over the shooting of Andre Hill, a ...

Another, called AZD9550, targets the gut hormone GLP-1 and a second obesity-related hormone called glucagon. Trials showed both were safe and tolerable, AstraZeneca said, adding it had begun Phase ...

Apollo forecasts assets under management to increase to $1.5 trillion by 2029 and remains on track to reach its prior goal of $1 trillion by 2026. The firm oversaw $696 billion as of June 30.

The largest book publisher in The Netherlands has confirmed ... The Bookseller contacted Simon & Schuster to ask if VBK’s AI translation trial had any wider implications for its parent business ...

A first group of healthy adults has been dosed in a Phase 1 safety and tolerability trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis (MS), regardless of ...